The impact of NAFLD on diabetic complications in patients with T2DM
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252157Keywords:
NAFLD, Type 2 diabetes mellitus, Coronary artery disease, Hypertension, Microvascular complications, Diabetic retinopathyAbstract
Background: This study investigates the relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, focusing on the associated macrovascular and microvascular complications. The aim is to assess the impact of the temporal sequence of these conditions on patient outcomes.
Methods: An observational study was conducted over three months (October 2023 to December 2023) at Katihar Medical College, enrolling 91 patients diagnosed with type 2 diabetes and NAFLD. Participants were grouped based on the duration of NAFLD and type 2 diabetes, and a range of clinical, laboratory, and diagnostic assessments were conducted to evaluate macrovascular and microvascular complications. Statistical analyses were performed to compare the groups.
Results: The study found that Group C had significantly higher BMI, WHR, triglycerides, ALT, AST, γ-GT, and uric acid levels compared to Groups A and B. The prevalence of CAD and hypertension was significantly higher in Group C. Group B had a longer NAFLD duration and higher ALT and AST levels than Group A. These findings suggest a strong association between metabolic dysfunction, NAFLD, and diabetic complications.
Conclusion: The study concludes that the temporal sequence of NAFLD and type 2 diabetes significantly influences the prevalence of macrovascular complications, particularly coronary artery disease and hypertension, in affected patients.
Metrics
References
Adams LA, Angulo P, Lindor KD. Non-alcoholic fatty liver disease. CMAJ. 2005;172:899–905. DOI: https://doi.org/10.1503/cmaj.045232
Hou XH, Zhu YX, Lu HJ, Chen HF, Li Q, Jiang S, et al. Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol. 2011;26(4):722-30. DOI: https://doi.org/10.1111/j.1440-1746.2010.06509.x
Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A. Asia-Pacific Working Party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific. J Gastroenterol Hepatol. 2007;22(6):794-800. DOI: https://doi.org/10.1111/j.1440-1746.2007.04952.x
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL; Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences. J Gastroenterol Hepatol. 2007;22(6):788-93. DOI: https://doi.org/10.1111/j.1440-1746.2007.05042.x
Fan JG, Farrell GC. Epidemiology of non–alcoholic fatty liver disease in China. J Hepatol. 2009;50:204–10. DOI: https://doi.org/10.1016/j.jhep.2008.10.010
Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: Prevalence and general characteristics. Diabetes Care. 2003;26:3351–2. DOI: https://doi.org/10.2337/diacare.26.12.3351-a
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19(8):854-8. DOI: https://doi.org/10.1111/j.1440-1746.2004.03312.x
Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-9. DOI: https://doi.org/10.1111/j.1478-3231.2008.01718.x
Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262-5. DOI: https://doi.org/10.1016/S1542-3565(04)00014-X
Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212-8. DOI: https://doi.org/10.2337/dc06-2247
Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25(4):476-81. DOI: https://doi.org/10.1111/j.1464-5491.2008.02410.x
El Azeem H, Khalek E-S, El-Akabawy H. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc. 2013;25:239–46. DOI: https://doi.org/10.1016/j.jsha.2013.07.004
Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care. 2012;35(11):2359-64. DOI: https://doi.org/10.2337/dc12-0515
Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest. 2006;29(1):55-60. DOI: https://doi.org/10.1007/BF03349177
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29(6):1325-30. DOI: https://doi.org/10.2337/dc06-0135
Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009;204:521-5. DOI: https://doi.org/10.1016/j.atherosclerosis.2008.09.012
Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012;35(2):389-95. DOI: https://doi.org/10.2337/dc11-1820
Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95. DOI: https://doi.org/10.1210/jc.2012-3093
Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis. 2010;20(8):583-90. DOI: https://doi.org/10.1016/j.numecd.2009.05.012
Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51(6):1979-87. DOI: https://doi.org/10.1002/hep.23593
Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's heart and health study and meta-analysis. Diabetes Care. 2009;32(4):741-50. DOI: https://doi.org/10.2337/dc08-1870
Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-49. DOI: https://doi.org/10.3109/07853890.2010.518623
Xie Y, Wang M, Zhang Y, Zhang S, Tan A, Gao Y, et al. Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PLoS One. 2013;8(7):67152. DOI: https://doi.org/10.1371/journal.pone.0067152
Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13(10):1579-84. DOI: https://doi.org/10.3748/wjg.v13.i10.1579
Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22(10):1354-8. DOI: https://doi.org/10.1111/j.1464-5491.2005.01646.x
Yan L, Wang S, Fu Y, Wang X, Zheng X, Zheng Y, et al. The impact of non-alcoholic fatty liver disease on islet function in type 2 diabetes. Zhonghua Nei Ke Za Zhi. 2015;54(3):197-200.
Wu SJ, Zou H, Zhu GQ, Wang LR, Zhang Q, Shi KQ, et al. Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. Medicine (Baltimore). 2015;94(19):842. DOI: https://doi.org/10.1097/MD.0000000000000842
Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of non-alcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207-14. DOI: https://doi.org/10.1097/HJH.0000000000000532
Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60:1040–5. DOI: https://doi.org/10.1016/j.jhep.2014.01.009
Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Australas Med J. 2013;6:325–30. DOI: https://doi.org/10.4066/AMJ.2013.1648
Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol. 2012;4:327–31. DOI: https://doi.org/10.4254/wjh.v4.i12.327
Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, et al. A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. PLoS One. 2015;10(11):143560. DOI: https://doi.org/10.1371/journal.pone.0143560
Lv WS, Sun RX, Gao YY, Wen JP, Pan RF, Li L, et al. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol. 2013;19(20):3134-42. DOI: https://doi.org/10.3748/wjg.v19.i20.3134
Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2014;5(2):170-5. DOI: https://doi.org/10.1111/jdi.12139
Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444-50. DOI: https://doi.org/10.1007/s00125-007-0897-4
Downloads
Published
How to Cite
Issue
Section
